UB Paderborn / Katalog / Suche / in CDI

A New Molecular Predictor of Distant Recurrence in ER-Positive, HER2-Negative Breast Cancer Adds Independent Information to Conventional Clinical Risk Factors

Clinical cancer research, 2011-09, Vol.17 (18), p.6012-6020

2011

Link zum Volltext

Verfügbarkeit prüfen

Prognostic Impact of Circulating Tumor Cells for Breast Cancer Patients Treated in the Neoadjuvant "Geparquattro" Trial

Clinical cancer research, 2017-09, Vol.23 (18), p.5384-5393

2017

Link zum Volltext

Verfügbarkeit prüfen

Mutational Diversity and Therapy Response in Breast Cancer: A Sequencing Analysis in the Neoadjuvant GeparSepto Trial

Clinical cancer research, 2019-07, Vol.25 (13), p.3986-3995

2019

Link zum Volltext

Verfügbarkeit prüfen

A Small Hypoxia Signature Predicted pCR Response to Bevacizumab in the Neoadjuvant GeparQuinto Breast Cancer Trial

Clinical cancer research, 2020-04, Vol.26 (8), p.1896-1904

2020

Link zum Volltext

Verfügbarkeit prüfen

Promoting Individual Well-Being, Increasing Social Welfare, and Securing Genetic Diversity Simultaneously: It Is a Matter of Degree

American journal of bioethics, 2015-06, Vol.15 (6), p.36-37

Weber, Karsten

2015

Link zum Volltext

Verfügbarkeit prüfen

Ethische Problemlagen durch die Verlegung sterbender Menschen zwischen verschiedenen Versorgungsorten und -einrichtungen

Zeitschrift für medizinische Ethik, 2020-01, Vol.66 (2), p.213-222

2020

Link zum Volltext

Verfügbarkeit prüfen

Machine Learning Healthcare Applications (ML-HCAs) Are No Stand-Alone Systems but Part of an Ecosystem - A Broader Ethical and Health Technology Assessment Approach is Needed

American journal of bioethics, 2020-11, Vol.20 (11), p.46-48

2020

Link zum Volltext

Verfügbarkeit prüfen

Methods for Practising Ethics in Research and Innovation: A Literature Review, Critical Analysis and Recommendations

Science and engineering ethics, 2018-10, Vol.24 (5), p.1437-1481

2018

Link zum Volltext

Verfügbarkeit prüfen

Is It All About Revising, Correcting, and Transferring Genes?

American journal of bioethics, 2020-08, Vol.20 (8), p.30-32

2020

Link zum Volltext

Verfügbarkeit prüfen

Challenges of Citizen Science: Commons, Incentives, Organizations, and Regulations

American journal of bioethics, 2019-08, Vol.19 (8), p.52-54

2019

Link zum Volltext

Verfügbarkeit prüfen

Digital Medicine, Cybersecurity, and Ethics: An Uneasy Relationship

American journal of bioethics, 2018-09, Vol.18 (9), p.52-53

2018

Link zum Volltext

Verfügbarkeit prüfen

Technique Tip: Avoiding Wound Complications After Neglected Achilles Tendon Repair Using a Tissue Expansion Technique

Foot & ankle international, 2007-03, Vol.28 (3), p.393-395

2007

Link zum Volltext

Verfügbarkeit prüfen

Cybersecurity in health – disentangling value tensions

Journal of information, communication & ethics in society (Online), 2019-09, Vol.17 (2), p.229-245

2019

Link zum Volltext

Verfügbarkeit prüfen

Detection of circulating tumor DNA following neoadjuvant chemotherapy and surgery to anticipate early relapse in ER positive and HER2 negative breast cancer: Analysis from the PENELOPE-B trial

Journal of clinical oncology, 2023-06, Vol.41 (16_suppl), p.502-502

2023

Link zum Volltext

Verfügbarkeit prüfen

Low TMB as predictor for additional benefit from neoadjuvant immune checkpoint inhibition in triple-negative breast cancer

Journal of clinical oncology, 2022-06, Vol.40 (16_suppl), p.581-581

2022

Link zum Volltext

Verfügbarkeit prüfen

Subgroup of post-neoadjuvant luminal-B tumors assessed by HTG in PENELOPE-B investigating palbociclib in high risk HER2-/HR+ breast cancer with residual disease

Journal of clinical oncology, 2021-05, Vol.39 (15_suppl), p.519-519

2021

Link zum Volltext

Verfügbarkeit prüfen

Abstract P5-13-36: Germline BRCA 1/2 and other predisposition genes in high-risk early-stage HR+/HER2- breast cancer (BC) patients treated with endocrine therapy (ET) with or without palbociclib: A secondary analysis from the PENELOPE-B study

Cancer research (Chicago, Ill.), 2022-02, Vol.82 (4_Supplement), p.P5-P5-13-36

2022

Link zum Volltext

Verfügbarkeit prüfen

Menü

Weitere Dienste

Einstellungen

A New Molecular Predictor of Distant Recurrence in ER-Positive, HER2-Negative Breast Cancer Adds Independent Information to Conventional Clinical Risk Factors

Prognostic Impact of Circulating Tumor Cells for Breast Cancer Patients Treated in the Neoadjuvant "Geparquattro" Trial

BRCA1/2 Mutations and Bevacizumab in the Neoadjuvant Treatment of Breast Cancer: Response and Prognosis Results in Patients With Triple-Negative Breast Cancer From the GeparQuinto Study

Mutational Diversity and Therapy Response in Breast Cancer: A Sequencing Analysis in the Neoadjuvant GeparSepto Trial

Gene Expression-Based Prediction of Neoadjuvant Chemotherapy Response in Early Breast Cancer: Results of the Prospective Multicenter EXPRESSION Trial

Caveolin Gene Expression Predicts Clinical Outcomes for Early-Stage HER2-Negative Breast Cancer Treated with Paclitaxel-Based Chemotherapy in the GeparSepto Trial

A Small Hypoxia Signature Predicted pCR Response to Bevacizumab in the Neoadjuvant GeparQuinto Breast Cancer Trial

Promoting Individual Well-Being, Increasing Social Welfare, and Securing Genetic Diversity Simultaneously: It Is a Matter of Degree

Ethische Problemlagen durch die Verlegung sterbender Menschen zwischen verschiedenen Versorgungsorten und -einrichtungen

Machine Learning Healthcare Applications (ML-HCAs) Are No Stand-Alone Systems but Part of an Ecosystem - A Broader Ethical and Health Technology Assessment Approach is Needed

Methods for Practising Ethics in Research and Innovation: A Literature Review, Critical Analysis and Recommendations

Is It All About Revising, Correcting, and Transferring Genes?

Challenges of Citizen Science: Commons, Incentives, Organizations, and Regulations

Digital Medicine, Cybersecurity, and Ethics: An Uneasy Relationship

Technique Tip: Avoiding Wound Complications After Neglected Achilles Tendon Repair Using a Tissue Expansion Technique

Immune-related Gene Expression Predicts Response to Neoadjuvant Chemotherapy but not Additional Benefit from PD-L1 Inhibition in Women with Early Triple-negative Breast Cancer

Cybersecurity in health – disentangling value tensions

Inferred Immune-Cell Activity Is an Independent Predictor of HER2-Negative Breast Cancer Prognosis and Response to Paclitaxel-Based Therapy in the GeparSepto Trial

Detection of circulating tumor DNA following neoadjuvant chemotherapy and surgery to anticipate early relapse in ER positive and HER2 negative breast cancer: Analysis from the PENELOPE-B trial

Low TMB as predictor for additional benefit from neoadjuvant immune checkpoint inhibition in triple-negative breast cancer

Subgroup of post-neoadjuvant luminal-B tumors assessed by HTG in PENELOPE-B investigating palbociclib in high risk HER2-/HR+ breast cancer with residual disease

Abstract P5-13-36: Germline BRCA 1/2 and other predisposition genes in high-risk early-stage HR+/HER2- breast cancer (BC) patients treated with endocrine therapy (ET) with or without palbociclib: A secondary analysis from the PENELOPE-B study

Abstract PD2-04: Molecular plasticity of luminal breast cancer and response to CDK 4/6 inhibition - The biomarker program of the PENELOPE-B trial investigating post-neoadjuvant palbociclib

Correlation of the tumor mutational burden with the composition of the immune cell subpopulations in peripheral blood of triple-negative breast cancer patients undergoing neoadjuvant therapy with durvalumab: Results from the prospectively randomized GeparNuevo trial

Abstract PD5-08: Tumor immune-cell activity assessed by RNAseq is an independent predictor of therapy response and prognosis after neoadjuvant chemotherapy in HER2 negative breast cancer patients - An analysis of the GeparSepto trial

Aktive Filter

Suchergebnisse filtern